



Merck in Canada

• Prescription products

Merck invests billions of research dollars to find medicines that can help change lives. Today, Merck has more than 80 prescription products in key therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease and women's health.

• Vaccines

We are one of the few companies that remain dedicated to advancing the complex business of researching and producing vaccines. Our unique contribution includes prevention of now-rare diseases such as measles and mumps, and of diseases that were once considered unpreventable, such as shingles and cervical cancer.

• Animal health

For domestic and farm animals, including dogs, cats, horses, cattle, sheep, pigs, poultry and fish, we offer a broad choice of vaccines, anti-infective and antiparasitic drugs, a complete range of fertility management products, performance technologies, pharmaceutical specialty products, innovative delivery solutions, and value-added programs.

Merck is a global health care leader

Merck is a global pharmaceutical company, that is research-based and dedicated to patients in more than 140 countries.

Merck delivers innovative health solutions through its prescription medicines, vaccines, biological therapies and animal health products that aim to improve well-being and life expectancy.

Our commitment to expanding access to health care translates into far-reaching policies, programs and partnerships that help the world be well.

A proud research tradition in Canada and around the world

Clinical trials

Canada is one of Merck's top locations for clinical research. As at December 31, 2015, Merck had some 58 clinical trial programs, involving over 4,000 patients, in progress at more than 277 establishments in Canada.

New R&D model

In line with our new R&D vision, we have shifted our approach from conducting in-house vertically integrated research to forming partnerships with Canadian universities, hospitals and biotech businesses. This new model's objective is to foster the development of innovations that improve the health of patients around the world.

Contribution to the fight against Ebola

Our investigational Ebola vaccine, rVSV-EBOV, initially engineered with support from the Public Health Agency of Canada, is in three large-scale clinical trials being conducted with partners in some of the hardest-hit countries in West Africa, including Guinea, Liberia and Sierra Leone.

> **US \$1.543 billion**
Merck worldwide philanthropic contributions in 2014.

In 2014, Merck allocated more than **\$3.5 million** in donations, grants and patient assistance programs in Canada.

> **\$1 billion**
R&D investments in the Canadian knowledge-based economy since 2000.



125
YEARS
SINCE 1891

A New Way, Every Day

© 2016 Merck Canada Inc. All rights reserved.
Merck Canada Inc. 16750 Trans-Canada Hwy.,
Kirkland, Quebec H9H 4M7

www.merck.ca